Amsbio expands drug discovery portfolio with comprehensive compound libraries
AMS Biotechnology (Amsbio) has unveiled an extensive collection of over 325,000 pre-characterised chemical compounds designed to accelerate drug screening applications across discovery and development programmes.
Validated compound libraries target diverse therapeutic areas
The comprehensive portfolio spans individual inhibitors, agonists, and natural products, alongside ready-to-screen compound libraries tailored for both academic and industrial research laboratories. Amsbio’s catalogue features more than 20,000 small molecule inhibitors and agonists, specifically selected for their membrane permeability, chemical stability, and versatility in both in vitro and in vivo investigations.
Research applications encompass apoptosis, autophagy, cell cycle regulation, immunology, and signalling cascades. The company’s curated libraries include over 800 compound collections covering focused bioactive compounds, natural products, fragments, and diversity sets, each designed to explore specific biological targets or chemical space.
Natural products collection supports therapeutic research
Amsbio supplies over 16,000 natural products, including flavonoids, alkaloids, terpenoids, coumarins, and saponins, targeting oncology, infectious disease, neurobiology, and metabolic research applications. All compounds are provided with comprehensive quality assurance data, including HNMR, HPLC, and GC analyses to confirm structural accuracy and purity.
PROTAC molecules enhance target engagement
The portfolio includes Proteolysis Targeting Chimeras (PROTACs), heterobifunctional molecules that degrade target proteins by hijacking the ubiquitin-proteasome system. “PROTACs often exhibit enhanced target engagement compared to traditional small molecule inhibitors due to their ability to induce proximity-driven ubiquitination of the target protein,” the company says.
The compound range is available in various pack sizes and remains searchable by CAS number, name, and product code to accommodate diverse drug discovery requirements.
For more information, visit: https://shorturl.at/SnCOt
Digital issue: Please click here for more information
